Perceptive Capital Solutions (NASDAQ:PCSC – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Valuation & Earnings
This table compares Perceptive Capital Solutions and Neuphoria Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Perceptive Capital Solutions | N/A | N/A | $840,000.00 | ($0.06) | -199.17 |
| Neuphoria Therapeutics | $15.65 million | 1.36 | -$370,000.00 | ($11.06) | -0.36 |
Profitability
This table compares Perceptive Capital Solutions and Neuphoria Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Perceptive Capital Solutions | N/A | -2.70% | -0.84% |
| Neuphoria Therapeutics | N/A | -76.93% | -54.76% |
Volatility and Risk
Perceptive Capital Solutions has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
Institutional and Insider Ownership
15.9% of Neuphoria Therapeutics shares are held by institutional investors. 22.1% of Perceptive Capital Solutions shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Perceptive Capital Solutions and Neuphoria Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Perceptive Capital Solutions | 1 | 0 | 0 | 0 | 1.00 |
| Neuphoria Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 431.65%. Given Neuphoria Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Perceptive Capital Solutions.
Summary
Neuphoria Therapeutics beats Perceptive Capital Solutions on 7 of the 12 factors compared between the two stocks.
About Perceptive Capital Solutions
Perceptive Capital Solutions Corp is a blank check company. It formed for the purpose of entering into a combination with one or more businesses or entities. Perceptive Capital Solutions Corp is based in NEW YORK.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Receive News & Ratings for Perceptive Capital Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perceptive Capital Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
